Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
251 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2016', provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections - The report reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Respiratory Syncytial Virus (RSV) Infections therapeutics and enlists all their major and minor projects - The report assesses Respiratory Syncytial Virus (RSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Respiratory Syncytial Virus (RSV) Infections Overview 11 Therapeutics Development 12 Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview 12 Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis 13 Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies 14 Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes 18 Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies 22 Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes 27 Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 28 Ablynx NV 28 ADMA Biologics, Inc. 29 Agilvax, Inc. 30 Aridis Pharmaceuticals LLC 31 Artificial Cell Technologies, Inc. 32 AstraZeneca Plc 33 Aviragen Therapeutics, Inc. 34 Bavarian Nordic A/S 35 Celltrion, Inc. 36 Codagenix, Inc. 37 CureVac GmbH 38 DBV Technologies S.A. 39 Emergent BioSolutions Inc. 40 Enanta Pharmaceuticals, Inc. 41 Evec, Inc. 42 F. Hoffmann-La Roche Ltd. 43 GenVec, Inc. 44 Gilead Sciences, Inc. 45 GlaxoSmithKline Plc 46 Globavir Biosciences, Inc. 47 Humabs BioMed SA 48 iBio, Inc. 49 ILiAD Biotechnologies, LLC 50 Ilyang Pharmaceutical Co., Ltd 51 Immunovaccine, Inc. 52 Inovio Pharmaceuticals, Inc. 53 Johnson & Johnson 54 Kineta, Inc. 55 mAbxience S.A. 56 MedImmune, LLC 57 Medivir AB 58 Merck & Co., Inc. 59 Mucosis B.V. 60 NanoBio Corporation 61 Navigen Pharmaceuticals, Inc. 62 Novavax, Inc. 63 Panacea Biotec Limited 64 Profectus BioSciences, Inc. 65 Pulmocide Ltd 66 Regeneron Pharmaceuticals, Inc. 67 Romark Laboratories, L.C. 68 Sirnaomics, Inc. 69 Spider Biotech 70 Spring Bank Pharmaceuticals, Inc. 71 Takeda Pharmaceutical Company Limited 72 TechnoVax, Inc. 73 The International Biotechnology Center (IBC) Generium 74 Trellis Bioscience, Inc. 75 Vault Pharma Inc. 76 Vaxart, Inc. 77 VaxInnate Corporation 78 VBI Vaccines Inc. 79 Virometix AG 80 Visterra, Inc. 81 VLP Biotech, Inc. 82 Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 83 Assessment by Monotherapy Products 83 Assessment by Combination Products 84 Assessment by Target 85 Assessment by Mechanism of Action 87 Assessment by Route of Administration 89 Assessment by Molecule Type 91 Drug Profiles 93 (human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile 93 (influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile 94 AK-0529 - Drug Profile 95 ALS-8112 - Drug Profile 96 ALS-8176 - Drug Profile 97 ALX-0171 - Drug Profile 98 Antisense RNAi Oligonucleotides for RSV and Viral Respiratory Tract Infections - Drug Profile 100 AR-201 - Drug Profile 101 AZ-27 - Drug Profile 102 BTAC-585 - Drug Profile 103 danirixin - Drug Profile 104 DPX-RSV - Drug Profile 106 EV-046120 - Drug Profile 107 EV-046135 - Drug Profile 108 GBV-006 - Drug Profile 109 GNR-007 - Drug Profile 110 GSK-3003891A - Drug Profile 111 GSK-3389245A - Drug Profile 112 GV-2311 - Drug Profile 113 GXV - Drug Profile 114 influenza + RSV vaccine - Drug Profile 115 IYS-21001 - Drug Profile 116 JNJ-53718678 - Drug Profile 117 JNJ-61187165AAA - Drug Profile 118 JNJ-61187191AAA - Drug Profile 119 KIN-1400 - Drug Profile 120 MEDI-7510 - Drug Profile 121 MEDI-8897 - Drug Profile 122 Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 123 Monoclonal Antibody for Respiratory Syncytial Virus - Drug Profile 124 Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 125 MPE-8 - Drug Profile 126 MV-012968 - Drug Profile 127 MVA-RSV - Drug Profile 128 nitazoxanide CR - Drug Profile 129 Oligonucleotide for respiratory syncytial virus vaccine - Drug Profile 131 Oligonucleotide for Respiratory Syncytial Virus-1 Infection - Drug Profile 132 palivizumab biosimilar - Drug Profile 133 palivizumab biosimilar - Drug Profile 134 palivizumab biosimilar - Drug Profile 135 palivizumab biosimilar - Drug Profile 136 PC-786 - Drug Profile 137 pertussis [strain BPZE1] vaccine - Drug Profile 138 presatovir - Drug Profile 140 Recombinant Protein for Respiratory Syncytial Virus - Drug Profile 141 Recombinant Protein for RSV Infections - Drug Profile 142 respiratory syncytial virus (virus like particle) vaccine - Drug Profile 143 respiratory syncytial virus (virus like particle) vaccine - Drug Profile 144 respiratory syncytial virus (virus like particle) vaccine - Drug Profile 145 respiratory syncytial virus (virus like particle) vaccines - Drug Profile 146 respiratory syncytial virus [strain 98-25147-X] vaccine - Drug Profile 147 respiratory syncytial virus vaccine - Drug Profile 148 respiratory syncytial virus vaccine - Drug Profile 149 respiratory syncytial virus vaccine - Drug Profile 152 respiratory syncytial virus vaccine - Drug Profile 153 respiratory syncytial virus vaccine - Drug Profile 154 respiratory syncytial virus vaccine - Drug Profile 155 respiratory syncytial virus vaccine - Drug Profile 156 respiratory syncytial virus vaccine - Drug Profile 157 respiratory syncytial virus vaccine - Drug Profile 158 respiratory syncytial virus vaccine - Drug Profile 159 respiratory syncytial virus vaccine - Drug Profile 160 respiratory syncytial virus vaccine - Drug Profile 161 respiratory syncytial virus vaccine - Drug Profile 162 respiratory syncytial virus vaccine - Drug Profile 163 respiratory syncytial virus vaccine - Drug Profile 164 respiratory syncytial virus vaccine - Drug Profile 165 respiratory syncytial virus vaccine - Drug Profile 166 respiratory syncytial virus vaccine - Drug Profile 167 respiratory syncytial virus vaccine - Drug Profile 168 respiratory syncytial virus vaccine - Drug Profile 169 respiratory syncytial virus vaccine - Drug Profile 170 respiratory syncytial virus vaccine - Drug Profile 171 Respiratory Syncytial Virus Vaccine - Drug Profile 172 respiratory syncytial virus vaccine - Drug Profile 173 respiratory syncytial virus vaccine - Drug Profile 174 respiratory syncytial virus vaccine 1 - Drug Profile 175 respiratory syncytial virus vaccine 1 - Drug Profile 176 respiratory syncytial virus vaccine 2 - Drug Profile 177 respiratory syncytial virus vaccine 2 - Drug Profile 178 RI-002 - Drug Profile 179 RSV-001 - Drug Profile 181 RV-521 - Drug Profile 182 SB-105-A10 - Drug Profile 183 SB-9200 - Drug Profile 185 Small Molecule for RSV - Drug Profile 187 Small Molecules for Respiratory Syncytial Virus - Drug Profile 188 Small Molecules for Respiratory Syncytial Virus Infections - Drug Profile 189 Small Molecules for RSV and Influenza A Infections - Drug Profile 190 Small Molecules for RSV Infections - Drug Profile 191 Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile 192 STP-902 - Drug Profile 193 suptavumab - Drug Profile 194 SynGEM - Drug Profile 196 Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection - Drug Profile 197 TRL-3D3 - Drug Profile 198 TVX-004IP - Drug Profile 199 VIS-RSV - Drug Profile 200 VMT-3 - Drug Profile 201 VPI-251 - Drug Profile 202 Respiratory Syncytial Virus (RSV) Infections - Recent Pipeline Updates 203 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 230 Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 234 Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 235 Featured News & Press Releases 235 Appendix 243 Methodology 243 Coverage 243 Secondary Research 243 Primary Research 243 Expert Panel Validation 243 Contact Us 243 Disclaimer 244
List of Tables
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2016 19 Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2016 20 Number of Products under Development by Companies, H1 2016 21 Number of Products under Development by Companies, H1 2016 (Contd..1) 22 Number of Products under Development by Companies, H1 2016 (Contd..2) 23 Number of Products under Development by Companies, H1 2016 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H1 2016 25 Comparative Analysis by Late Stage Development, H1 2016 26 Comparative Analysis by Clinical Stage Development, H1 2016 27 Comparative Analysis by Early Stage Development, H1 2016 28 Products under Development by Companies, H1 2016 29 Products under Development by Companies, H1 2016 (Contd..1) 30 Products under Development by Companies, H1 2016 (Contd..2) 31 Products under Development by Companies, H1 2016 (Contd..3) 32 Products under Development by Companies, H1 2016 (Contd..4) 33 Products under Investigation by Universities/Institutes, H1 2016 34 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H1 2016 35 Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics, Inc., H1 2016 36 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H1 2016 37 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 38 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H1 2016 39 Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H1 2016 40 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aviragen Therapeutics, Inc., H1 2016 41 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H1 2016 42 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H1 2016 43 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H1 2016 44 Respiratory Syncytial Virus (RSV) Infections - Pipeline by CureVac GmbH, H1 2016 45 Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies S.A., H1 2016 46 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 47 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enanta Pharmaceuticals, Inc., H1 2016 48 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec, Inc., H1 2016 49 Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 50 Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H1 2016 51 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H1 2016 52 Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 53 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Globavir Biosciences, Inc., H1 2016 54 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H1 2016 55 Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H1 2016 56 Respiratory Syncytial Virus (RSV) Infections - Pipeline by ILiAD Biotechnologies, LLC, H1 2016 57 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ilyang Pharmaceutical Co., Ltd, H1 2016 58 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine, Inc., H1 2016 59 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 60 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H1 2016 61 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H1 2016 62 Respiratory Syncytial Virus (RSV) Infections - Pipeline by mAbxience S.A., H1 2016 63 Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune, LLC, H1 2016 64 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H1 2016 65 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co., Inc., H1 2016 66 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H1 2016 67 Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H1 2016 68 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 69 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H1 2016 70 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H1 2016 71 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Profectus BioSciences, Inc., H1 2016 72 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H1 2016 73 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 74 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H1 2016 75 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sirnaomics, Inc., H1 2016 76 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spider Biotech, H1 2016 77 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 78 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 79 Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H1 2016 80 Respiratory Syncytial Virus (RSV) Infections - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 81 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Trellis Bioscience, Inc., H1 2016 82 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vault Pharma Inc., H1 2016 83 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart, Inc., H1 2016 84 Respiratory Syncytial Virus (RSV) Infections - Pipeline by VaxInnate Corporation, H1 2016 85 Respiratory Syncytial Virus (RSV) Infections - Pipeline by VBI Vaccines Inc., H1 2016 86 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H1 2016 87 Respiratory Syncytial Virus (RSV) Infections - Pipeline by Visterra, Inc., H1 2016 88 Respiratory Syncytial Virus (RSV) Infections - Pipeline by VLP Biotech, Inc., H1 2016 89 Assessment by Monotherapy Products, H1 2016 90 Assessment by Combination Products, H1 2016 91 Number of Products by Stage and Target, H1 2016 93 Number of Products by Stage and Mechanism of Action, H1 2016 95 Number of Products by Stage and Route of Administration, H1 2016 97 Number of Products by Stage and Molecule Type, H1 2016 99 Respiratory Syncytial Virus (RSV) Infections Therapeutics - Recent Pipeline Updates, H1 2016 210 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2016 237 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..1), H1 2016 238 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..2), H1 2016 239 Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..3), H1 2016 240 Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H1 2016 241
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
